Design, synthesis and anti-tumor activity of matrine derivatives as Hsp90 inhibitors
- PMID: 40601056
- DOI: 10.1007/s12032-025-02858-3
Design, synthesis and anti-tumor activity of matrine derivatives as Hsp90 inhibitors
Abstract
This study investigates the effects of novel matrine derivatives as heat shock protein 90 (Hsp90) inhibitors on the proliferation, cloning, and migration ability of lung cancer A549 cells along with their mechanisms. In this work, we used matrine as a lead compound with the research objectives of improving its targeting and anti-tumor activity, as well as developing Hsp90 inhibitors with novel structures. We designed and synthesized 21 matrine derivatives based on the C-14 position of matrine. The antiproliferative activities of all compounds against three types of cancer cells were determined by MTT assay. Most of the compounds showed excellent anticancer activity compared to matrine. Among them, compound H10 showed the most potent antiproliferative activity with IC50 values of 4.541 ± 0.56 µM (MDA-MB-231), 6.784 ± 0.92 µM (Huh-7), and 3.585 ± 0.45 µM (A549), respectively. Compound H10 not only effectively suppresses the colony formation and migration of A549 cells but also significantly induces cell apoptosis. Subsequent, the impact of compound H10 on Hsp90 protein and proteins associated with the PI3K/Akt/mTOR signaling pathway was evaluated using Western blot analysis. The findings demonstrated that compound H10 effectively suppresses the expression of Hsp90 and induces apoptosis in lung cancer cells by inhibiting the PI3K/Akt/mTOR signaling pathway. This study indicated that compound H10 might serve as a lead compound of Hsp90 inhibitors for the treatment of lung cancers.
Keywords: Anti-tumor; Heat shock protein 90; Matrine; PI3K/Akt/mTOR signaling pathway.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests.
Similar articles
-
New modification strategy of matrine as Hsp90 inhibitors based on its specific L conformation for cancer treatment.Bioorg Med Chem. 2020 Feb 15;28(4):115305. doi: 10.1016/j.bmc.2020.115305. Epub 2020 Jan 7. Bioorg Med Chem. 2020. PMID: 31928863
-
Novel E-F ring derivatives of aconitine scaffold as potent Hsp90 inhibitors for the treatment of colorectal cancer.Eur J Med Chem. 2025 Oct 15;296:117895. doi: 10.1016/j.ejmech.2025.117895. Epub 2025 Jun 21. Eur J Med Chem. 2025. PMID: 40570414
-
Novel chiral matrine derivatives as potential antitumor agents: Design, synthesis and biological evaluation.Bioorg Chem. 2024 May;146:107276. doi: 10.1016/j.bioorg.2024.107276. Epub 2024 Mar 9. Bioorg Chem. 2024. PMID: 38479132
-
Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review.Int J Mol Sci. 2024 May 17;25(10):5468. doi: 10.3390/ijms25105468. Int J Mol Sci. 2024. PMID: 38791506 Free PMC article.
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
References
-
- Wang Z, Zhi K, Ding Z, et al. Emergence in protein derived nanomedicine as anticancer therapeutics: more than a tour de force [J]. Semin Cancer Biol. 2021;69:77–90.
-
- Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer [J]. The Lancet. 2021;398(10299):535–54.
-
- Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer [J]. Open Biol. 2017;7(9): 170070.
-
- Gao S, Li J, Wang W, et al. Rabdosia rubescens (Hemsl.) H. Hara: a potent anti-tumor herbal remedy—botany, phytochemistry, and clinical applications and insights [J]. J Ethnopharmacol. 2025;340: 119200.
-
- Li Y, Yang G, Li Q, et al. Guiqi Baizhu decoction enhances radiosensitivity in non-small cell lung cancer by inhibiting the HIF-1α/DNA-PKcs axis-mediated DNA repair [J]. Phytomedicine. 2025;140: 156591.
MeSH terms
Substances
Grants and funding
- GXPPDS202403/Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
- GXPPDS202403/Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
- GXPPDS202403/Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
- GXPPDS202403/Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
- GXPPDS202403/Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
- GXPPDS202403/Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
- SSTLAB-2023-03/Shenzhen Key Laboratory of Southern Subtropical Plant Diversity
- SSTLAB-2023-03/Shenzhen Key Laboratory of Southern Subtropical Plant Diversity
- SSTLAB-2023-03/Shenzhen Key Laboratory of Southern Subtropical Plant Diversity
- SSTLAB-2023-03/Shenzhen Key Laboratory of Southern Subtropical Plant Diversity
- SSTLAB-2023-03/Shenzhen Key Laboratory of Southern Subtropical Plant Diversity
- SSTLAB-2023-03/Shenzhen Key Laboratory of Southern Subtropical Plant Diversity
- 202300011/Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province
- 202300011/Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province
- 202300011/Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province
- 202300011/Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province
- 202300011/Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province
- 202300011/Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province
LinkOut - more resources
Full Text Sources
Miscellaneous